172 related articles for article (PubMed ID: 32118591)
1. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia.
Paunescu H; Dima L; Ghita I; Coman L; Ifteni PI; Fulga I; Coman OA
Am J Ther; 2020; 27(3):e249-e269. PubMed ID: 32118591
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.
Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N
CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310
[TBL] [Abstract][Full Text] [Related]
3. Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis.
Ruthirakuhan M; Lanctôt KL; Vieira D; Herrmann N
J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30753761
[TBL] [Abstract][Full Text] [Related]
4. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol for agitation in dementia.
Lonergan E; Luxenberg J; Colford J
Cochrane Database Syst Rev; 2001; (4):CD002852. PubMed ID: 11687166
[TBL] [Abstract][Full Text] [Related]
6. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
Herrmann N; Cappell J; Eryavec GM; Lanctôt KL
CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments.
Liu CS; Ruthirakuhan M; Chau SA; Herrmann N; Carvalho AF; Lanctôt KL
Curr Alzheimer Res; 2016; 13(10):1134-44. PubMed ID: 27137221
[TBL] [Abstract][Full Text] [Related]
8. Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review.
Stella F; Valiengo LCL; Paula VJR; Lima CAM; Forlenza OV
Trends Psychiatry Psychother; 2021; 43(4):243-255. PubMed ID: 34374269
[TBL] [Abstract][Full Text] [Related]
9. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
Herrmann N; Gauthier S; Boneva N; Lemming OM;
Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological management for agitation and aggression in people with acquired brain injury.
Fleminger S; Greenwood RJ; Oliver DL
Cochrane Database Syst Rev; 2006 Oct; (4):CD003299. PubMed ID: 17054165
[TBL] [Abstract][Full Text] [Related]
12. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol for agitation in dementia.
Lonergan E; Luxenberg J; Colford J
Cochrane Database Syst Rev; 2002; (2):CD002852. PubMed ID: 12076456
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoids for Agitation in Alzheimer's Disease.
Outen JD; Burhanullah MH; Vandrey R; Amjad H; Harper DG; Patrick RE; May RL; Agronin ME; Forester BP; Rosenberg PB
Am J Geriatr Psychiatry; 2021 Dec; 29(12):1253-1263. PubMed ID: 33573996
[TBL] [Abstract][Full Text] [Related]
15. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
[TBL] [Abstract][Full Text] [Related]
16. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.
Trzepacz PT; Cummings J; Konechnik T; Forrester TD; Chang C; Dennehy EB; Willis BA; Shuler C; Tabas LB; Lyketsos C
Int Psychogeriatr; 2013 May; 25(5):707-19. PubMed ID: 23257314
[TBL] [Abstract][Full Text] [Related]
17. Advancements in the treatment of agitation in Alzheimer's disease.
Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
[TBL] [Abstract][Full Text] [Related]
18. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia.
Sommer OH; Aga O; Cvancarova M; Olsen IC; Selbaek G; Engedal K
Dement Geriatr Cogn Disord; 2009; 27(2):155-63. PubMed ID: 19182483
[TBL] [Abstract][Full Text] [Related]
19. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
[TBL] [Abstract][Full Text] [Related]
20. Electroconvulsive therapy (ECT) for treating agitation in dementia (major neurocognitive disorder) - a promising option.
Glass OM; Forester BP; Hermida AP
Int Psychogeriatr; 2017 May; 29(5):717-726. PubMed ID: 28095946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
